Botulinum toxin A in the hemiplegic upper limb: a double-blind trial

Area of Science:

• Neurology
• Physical Medicine & Rehabilitation
• Pediatrics

Background:

• Cerebral palsy (CP) often involves upper limb spasticity, impacting range of motion and function.
• Botulinum toxin type A (BtA) is a potential therapeutic agent for managing spasticity in CP.

Purpose of the Study:

• To evaluate the efficacy of intramuscular botulinum toxin type A (BtA) injections in the upper limb for children with cerebral palsy.
• To compare BtA effects against a normal saline placebo in terms of range of movement, function, and tone.

Main Methods:

• A randomised, double-blind study involving 14 pediatric patients with cerebral palsy (mean age 9 years).
• Intramuscular injections of BtA or normal saline into the upper limb.
• Assessment of range of movement and function at baseline, 2 weeks, and 12 weeks post-injection.

Main Results:

• BtA significantly enhanced active elbow and thumb extension and reduced wrist and elbow tone.
• Hand grasp-and-release scores showed modest improvement; fine motor skills (e.g., picking up coins) did not improve and sometimes temporarily worsened.
• Subjective benefits included cosmetic improvement from reduced involuntary elbow flexion, with clinically detectable tone reduction perceived as beneficial by patients and parents.

Conclusions:

• BtA injections demonstrate a clinically beneficial tone-reducing effect in selected pediatric CP patients with upper limb involvement.
• While improvements in range of motion and some functional aspects were observed, fine motor skills require further investigation.
• The wide range of outcomes suggests personalized treatment approaches for BtA therapy in cerebral palsy.